宜宾做欧式双眼皮多少钱宜宾医院有什么去祛斑,宜宾整容医院最鼻子最好,宜宾激光祛斑需多少钱,宜宾假体鼻子多少钱,宜宾双眼皮手术失败,宜宾激光嫩肤能去斑吗,宜宾缩小鼻翼手术

PARIS, May 17 (Xinhua) -- Arianespace has approved the preparation review of the third Ariane 5 flight, which is expected to lift two communication satellites on Friday from the spaceport in French Guiana, the European launching center said on Tuesday.The prior readiness review approved that "Ariane 5 is now cleared for its May 19 rollout from the Final Assembly Building to the ELA-3 launch zone, where it will be readied for liftoff on Friday at 5:38 p.m. local time in French Guiana," the space center said in a statement.This dual payload flight will orbit GSAT-8 and ST-2 satellites, with a combined mass of 8,190 kilo grams.Built by Japan's Mitsubishi Electric Company, ST-2 will be utilized by the ST-2 Satellite Ventures joint company of Singapore Telecommunications Ltd (SingTel) and Taiwan's Chunghwa Telecom Company Ltd. for Ku- and C-band relay services across the Middle East, Central Asia, India and Southeast Asia.The lighter passenger GSAT-8, built by the Indian Space Research Organization (ISRO), will serve to augment India's Ku- band relay capabilities and offer aircraft navigation assistance over Indian airspace and adjoining areas with its two-channel GAGAN system.The Arianespace started its 2011 busy year for heavy-lift Ariane 5 with the milestone launch of Europe's second Automated Transfer Vehicle (ATV) on February 16, and then a dual payload on April 22 that orbited Yahsat Y1A and Intelsat New Dawn satellites.

WASHINGTON, April 11 (Xinhua) -- Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.Each year, more than 230 million major elective surgeries are performed around the world. Unfortunately, many patients who undergo major operations develop kidney injury soon after surgery, often due to decreased blood flow to the kidneys and/or the effects of inflammation.Animal studies suggest that the cholesterol-lowering drugs called statins protect the kidneys from such damage, but whether a similar benefit occurs in humans is uncertain. To investigate, Amber Molnar, University of Western Ontario, and colleagues conducted a population-based retrospective study of all older patients who underwent major elective surgery in the province of Ontario, Canada from 1995 to 2008. Surgeries included cardiac, thoracic, vascular, intra-abdominal, and retroperitoneal procedures.A total of 213,347 patients from 211 hospitals underwent major elective surgery, and 4,020 patients (1.9 percent) developed postoperative kidney injury within two weeks of surgery. A total of 1,173 patients (0.5 percent) required dialysis within two weeks of surgery, and 5,974 patients (2.8 percent) died within a month of surgery.Prior to surgery, 67,941 patients (32 percent) were taking a statin. Patients taking a statin were 20 percent less likely to develop kidney injury, need dialysis, and die compared to patients who were not taking a statin. Also, there was evidence of a dose-effect, with patients on higher potency statins having less kidney injury. In addition, statins were beneficial whether they were started greater than 90 days or less than 30 days prior to surgery."Our study suggests that statin use in older persons results in less kidney injury following major elective surgery and reduces the risk of premature death after surgery," said Molnar, adding that the results warrant further investigation with more rigorous studies, but such trials will be difficult to carry out.

BEIJING, May 16 (Xinhuanet) -- NASA is close to deciding on a landing site for its Mars rover Curiosity mission by narrowing the choices to four, media reports said Monday.Scientists in the close-knit Mars research community get one last chance to make their case this week when they gather before the "judges" — the team running the 2.5 billion U.S. dollar mission that will soon suggest a landing site to NASA, the ultimate decider."All four of these places are compelling places on Mars to study. There's not a loser among them," said landing site scientist Matt Golombek of the NASA Jet Propulsion Laboratory, one of the meeting's leaders.The mission will use rover Curiosity to study whether a selected area will have environmental conditions suitable for life and for preserving evidence about whether extraterrestial life has existed.Being nuclear-powered, the rover cannot go to a location that has either water or ice within one meter of the surface.The size of a mini Cooper, Curiosity is scheduled to launch in late November after a two-year delay.

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.